Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tacrolimus-induced tinea incognito.

Narendra Siddaiah1, Quenby Erickson, Gea Miller

  • 1South Sound Inpatient Physicians, Browns Point, Washington 98422, USA. siddaiah@excite.com

Cutis
|May 12, 2004
PubMed
Summary

Topical tacrolimus, a nonsteroidal anti-inflammatory, may cause widespread tinea incognito, a fungal infection. This condition mimics corticosteroid-induced tinea incognito and can obscure diagnosis, even after partial griseofulvin treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pityriasis rubra pilaris.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the Editor: Understanding Confidence Intervals and the Limitations of Statistics.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the editor: Parametric and nonparametric tests.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the editor: Chi square.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the Editor: The null hypothesis.

Journal of the American Academy of Dermatology·2024
Same author

Letter from the Editor: Size matters.

Journal of the American Academy of Dermatology·2024

Area of Science:

  • Dermatology
  • Mycology
  • Pharmacology

Background:

  • Tacrolimus and pimecrolimus are novel topical nonsteroidal agents for inflammatory skin conditions.
  • Their efficacy in treating various dermatoses is established.
  • Understanding potential side effects is crucial for patient safety.

Observation:

  • A case study involving a patient treated with topical tacrolimus is presented.
  • The patient developed extensive lesions characteristic of tinea incognito.
  • The clinical presentation mimicked tinea incognito typically induced by topical corticosteroids.

Findings:

  • Topical tacrolimus therapy was associated with the development of widespread tinea incognito.
  • Partial treatment of dermatophytosis with griseofulvin complicated the diagnosis.

Related Experiment Videos

  • Topical tacrolimus demonstrated the potential to induce or exacerbate dermatophytosis.

    • Implications:

    • Clinicians should consider tinea incognito in patients using topical tacrolimus, especially with atypical presentations.
    • The immunosuppressive effects of topical tacrolimus may predispose to or worsen fungal infections.
    • Dermatophytosis management requires careful consideration of concurrent topical therapies.